# Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

> **NCT03782415** · PHASE1,PHASE2 · COMPLETED · sponsor: **MediciNova** · enrollment: 64 (actual)

## Conditions studied

- Glioblastoma
- Recurrent Glioblastoma
- GBM
- Newly Diagnosed Glioblastoma

## Interventions

- **DRUG:** MN-166
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03782415
- **Lead sponsor:** MediciNova
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-29
- **Primary completion:** 2023-08-07
- **Final completion:** 2023-08-07
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03782415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03782415, "Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03782415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*